课题基金 / 基金详情

PHASE II PILOT TRIAL OF CONCURRENT BIOCHEMOTHERAPY WITH CISPLATIN, DACARBAZINE

PHASE II PILOT TRIAL OF CONCURRENT BIOCHEMOTHERAPY WITH CISPLATIN, DACARBAZINE
顺铂、达卡巴嗪同步生物化疗的 II 期试点试验
批准号:
6245550
负责人:
Michael Benjamin Atkins
金额:
$2.82万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-05-01 至 1997-11-30

项目摘要

项目成果

Michael Benjamin Atkins的其他基金

相似基金

相关文献

中文摘要
翻译
这项研究将包括静脉注射DTIC,CDDP和 长春花碱同时皮下注射α-氨基丁酸 干扰素(Intron A)和连续四天的IL-2输注。这个 本研究的目的是确定DTIC的管理是否 顺铂、长春花碱联合IL-2持续输注 皮下注射干扰素能够产生 对肿瘤生长的影响。我们还希望确定这种药物的副作用 这种疗法以及实施这种治疗的潜在可行性 在社区医院环境中。
英文摘要
This study will involve the intravenous administration of DTIC, CDDP, and Vinblastine concurrent with subcutaneous administration of alpha- interferon (Intron A) and a four-day continous infusion of IL-2. The purpose of this study is to determine whether the administration of DTIC and CDDP and Vinblastine in combination with a continuous infusion of IL-2 and subcutaneous injections of interferon is capable of having an effect on the growth of tumors. We also hope to determine the side effects of this regimen and the potential feasibility of carrying out this treatment in community hospital settings.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
  • 批准号:
    10462570
  • 项目类别:
  • 资助金额:
    $52.27万
  • 财政年份:
    2018
  • 负责人:
    Michael Benjamin Atkins
  • 依托单位:
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
  • 批准号:
    10001451
  • 项目类别:
  • 资助金额:
    $53.33万
  • 财政年份:
    2018
  • 负责人:
    Michael Benjamin Atkins
  • 依托单位:
Career Development Program
Developmental Research Program
海外基金